logo-loader

Medical supply sector in focus after huge C.R. Bard, Becton combination

Last updated: 15:52 24 Apr 2017 EDT, First published: 10:52 24 Apr 2017 EDT

1-Operation
Healthcare and those that suppl,y hospitals were in focus after the mega-deal

US medical device giant C.R. Bard (NYSE:BCR) shares were up almost 20% on Monday as the medical device sector was thrown into focus, and the former agreed to be bought out.

It follows news that Bard will  be bought by fellow titan Becton, Dickinson and Co after the pair agreed to combine in an eye watering $24bn deal.

Two of the largest healthcare suppliers

It brings together two of the largest healthcare suppliers together and throws the spotlight firmly on the sector where there have been several acquisitions recently as firms look to expand their portfolios to get better profit margins due to pricing pressure.

Becton, Dickinson  will pay $317 a share for Bard in cash and shares.

That's about 25% more than Bard’s April 21 share closing price, the companies said at the weekend.

Both boards have reportedly unanimously agreed the deal.

Consolidation in the sector...

The deal comes two years after Becton Dickinson (NYSE: BDX), down 4.36% today,  acquired CareFusion Corp (NYSE:CFN) for $12bn and in January this year, Abbott Laboratories (NYSE:ABT), up 1.56% today,  acquired St Jude Medical Inc (NYSE:STJ) for $25 billion.

In 2015,  Zimmer Holdings Inc merged with Biomet Inc for $13.4 billion, creating Zimmer Biomet Holdings Inc (NYSE:ZBH), whose shares were up 1.67% on the day.

Speaking of the Bard deal today,  its chief executive Tim Ring said: "We are confident that this combination will deliver meaningful benefits for customers and patients, as we see opportunities to leverage Becton Dickinson's leadership, especially in medication management and infection prevention."

New Jersey based Becton Dickinson said it expected the acquisition to boost non-US growth options in markets, and to raise EPS (earnings per share) in fiscal year 2019.

With a larger portfolios, medical companies can offer hospitals and purchasers deals on products and services as they (hospitals) themselves merge into larger health systems and centralised operations.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

11 hours, 9 minutes ago